Navigation Links
CSL Behring Receives FDA Orphan Drug Designation for rVIIa-FP, a Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors
Date:2/16/2012

KING OF PRUSSIA, Pa., Feb. 16, 2012 /PRNewswire/ -- CSL Behring announced today that the company has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for its novel recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP). The Orphan Drug Designation is granted for the treatment and prophylaxis of bleeding episodes in patients with congenital hemophilia and inhibitors to coagulation factor VIII or IX. CSL Behring is developing this therapy in collaboration with its parent company CSL Limited (ASX: CSL).

The CSL Behring rVIIa-FP clinical program will soon be initiated and intends to demonstrate that an extended half-life rVIIa-FP will result in a requirement for fewer doses while providing adequate therapeutic response in patients who have hemophilia A and B with inhibitors.

"CSL Behring's albumin fusion technology uses albumin as the ideal recombinant genetic fusion partner for coagulation factor proteins because of its high tolerability, inherently long half-life, low potential for immunogenic reactions and known mechanism of clearance," said Russell Basser, M.D., Senior Vice President, Global Clinical R&D at CSL Behring. "CSL Behring's rVIIa albumin fusion protein is expected to exhibit a good tolerability profile and improved pharmacokinetics that may enable prophylaxis. We welcome Orphan Drug Designation for our rVIIa-FP and will work closely with the FDA to make this important therapy available for people in the U.S. with hemophilia A and hemophilia B with inhibitors."

The FDA's Orphan Drug Designation program provides orphan status to unique drugs and biologics, defined as those intended for the safe and effective treatment or prevention of rare dise
'/>"/>

SOURCE CSL Behring
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CSL Behring Receives FDA Approval of Expanded Label on Berinert® for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema
2. CSL Behring Seeks Proposals for Interlaken Leadership Awards, Supporting Innovative Research Into Neuroimmunology
3. CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A and B Treatment
4. National Organization for Rare Disorders Presents CSL Behring With 2011 Corporate Award
5. CSL Behring Marks World Hemophilia Day with Coagulation Factor Donation to World Federation of Hemophilia
6. CSL Behring Medical Product Donation Helps Meet Critical Need for Ongoing Cholera Relief Effort in Haiti
7. CSL Behring Announces Completion of National Marketing Authorizations of Berinert® After MRP in 23 European Countries
8. CSL Behring Announces FDA Approval of Berinert(R), First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Hereditary Angioedema in U.S.
9. CSL Behring Receives Orphan-Drug Exclusivity for RiaSTAP(TM), First and Only Approved Treatment of Acute Bleeding Episodes in Patients with Congenital Fibrinogen Deficiency
10. Over $10 Million of CSL Behrings Privigen Was Sold in the U.S. During the Third Quarter of 2008
11. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... , March 27, 2015 /PRNewswire/ - Medicure Inc. (the ... Directors has approved the grant of an aggregate of ... employees and consultants of the Company pursuant to the ... set to expire on the tenth anniversary of the ... the third anniversary of the date of grant and ...
(Date:3/27/2015)... Telbec/ - Russell Williams , President of ... the 2015-2016 Quebec Budget, noting the fiscal discipline and ... industry. However, the association is concerned about the decline ... government,s intent to strive for a balanced budget this ... Quebec,s economic development is encouraging," said ...
(Date:3/27/2015)... Biopharmaceutical Industry Leads Manufacturing Sector in R&D Spending ... as the country,s manufacturing leader in innovation and economic ... to the  analysis , the industry had the highest ... accounting for 27 percent of average annual R&D spending ... on Medicare Part D - Medicare Part D ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Week in Review: The Latest from PhRMA 2
... SPEX ) reported that patient recruitment for its Phase ... Naturlose(R), has begun in,India. Expectations for India are to ... the pivotal Phase 3 trial. "Now that enrollment efforts,are ... trial will be completed,on schedule as reported during the ...
... only participant in Texas for TFAS spinal implant, PLANO, ... again in motion preserving technology by continuing to advance,spinal device ... (TFAS)(R)., Dr. Barton Sachs of Texas Back Institute performed ... Texas resident was one of,the first 40 people worldwide to ...
Cached Medicine Technology:Patient Recruitment Begins in India for Phase 3 Diabetes Trial 2Texas Back Institute Leads Way in New Facet Joint Clinical Trial 2
(Date:3/30/2015)... 2015 Bunion Bootie is a ... for family members, friends...and yourself and save. For a limited ... an additional 10%, on top of discounts already offered when ... at checkout. The more Bunion Booties purchased, the more money ... bunion pads, Bunion Bootie can be worn comfortably and easily ...
(Date:3/29/2015)... March 29, 2015 Women’s Excellence ... treatment. Secondary to their location in Birmingham, they ... option. They continue to be affiliated with Crittenton, ... , Menopause is a normal condition that all women ... any of the changes a woman goes through either ...
(Date:3/29/2015)... The Claudia Cohen Research Foundation ... announce today that Dr. Beth Y. Karlan has been ... Research Foundation Prize for Outstanding Gynecologic Researcher. The $50,000 ... Oncology 46th Annual Meeting on Women's Cancer in Chicago. ... Cancer Program at the Samuel Oschin Comprehensive Cancer Institute ...
(Date:3/29/2015)... 2015 Final Cut Pro X ... Pixel Film Studios, entitled TranSports. , “TranSports is ... Final Cut Pro X,” said Christiana Austin, CEO of ... needed to effortlessly transition using this cool sports transition ... and uniquely styled transition pack for Final Cut Pro ...
(Date:3/28/2015)... Tucson, AZ. (PRWEB) March 28, 2015 ... according to a new study by researchers ... (HSPH). , Produced with the support of the Coffee ... the journal Molecular Psychiatry this past fall, the study—one ... a meta-analysis of genomic data from more than 120,000 ...
Breaking Medicine News(10 mins):Health News:Bunion Bootie, the Ultimate Solution for Bunion Relief, Offers Special Savings This Easter 2Health News:Women's Excellence Affiliates with Beaumont Hospital, Treats Menopause 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Introducing TranSports for Final Cut Pro X Users from Pixel Film Studios 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 2Health News:How Coffee Habits Relate to Our Genetic Code and Enhancing the Caffeine Experience 3
... hay fever symptoms could be reduced by 60% with the ... in Baltimore. ,Dr. Peter Socrates Creticos, medical director ... Johns Hopkins University School of Medicine and his team tested ... ,The study was conducted on 25 volunteers with ...
... health shops to overcome depression only one actually has any ... have said that St John's Wort is the only alternative ... others including gingko biloba, ginseng, cat's claw, royal jelly and ... serious drug interactions". ,The experts, Joyce Reed, a ...
... a dozen top universities on Tuesday by the government ... hasten scientific discoveries towards better health care thereby trying ... ,This idea came about because of the increased specialization ... ever for scientists from different fields to share the ...
... the All India Institute of Medical Sciences (AIIMS), including ... postponed its medical students' semester examination scheduled for later ... their hostel rooms after a seventh semester student died ... virus include medical students, resident doctors and other hospital ...
... and biotech major Wockhardt Limited announced on Tuesday ... $150 million that will help it broaden its presence ... a larger footprint in Europe spread over Britain, Ireland ... ,'European business will now exceed $200 million, accounting for ...
... tuberculosis that caused a major outbreak in a British school ... has surfaced again, directing its destruction on a specific ethnic ... a study to examine the potency of the 2001 outbreak. ... disease with the BCG vaccine. ,The severe strain, ...
Cached Medicine News:Health News:DNA vaccine for ragweed allergies 2Health News:Unscientific Depression Drugs aplenty in Health Stores 2Health News:NIH Funds the Development of National Consortium of Universities 2
... Used for temporary ... ureteropelvic junction to the ... peel-open packages. Intended for ... evaluation is advised; C-Flex® ...
Used for antegrade placement of a safety wire guide prior to endourological procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Used when establishing a percutaneous tract for nephrostomy drainage. The guide has a stiff shaft and a gradual transition to a very flexible distal tip. Supplied sterile in peel-open packages. Inten...
Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: